This article first appeared on GuruFocus.

Orchestra BioMed Holdings Inc (NASDAQ:OBIO) is set to release its Q3 2025 earnings on Nov 12, 2025. The consensus estimate for Q3 2025 revenue is $0.76 million, and the earnings are expected to come in at -$0.42 per share. The full year 2025's revenue is expected to be $3.40 million and the earnings are expected to be -$1.78 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 5 Warning Signs with OBIO.

Is OBIO fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Orchestra BioMed Holdings Inc (NASDAQ:OBIO) have increased from $3.12 million to $3.40 million for the full year 2025 and from $3.47 million to $3.77 million for 2026 over the past 90 days. Earnings estimates have improved from -$1.99 per share to -$1.78 per share for the full year 2025 and from -$1.75 per share to -$1.54 per share for 2026 over the past 90 days.

In the previous quarter of 2025-06-30, Orchestra BioMed Holdings Inc's (NASDAQ:OBIO) actual revenue was $0.84 million, which beat analysts' revenue expectations of $0.70 million by 20.11%. Orchestra BioMed Holdings Inc's (NASDAQ:OBIO) actual earnings were -$0.50 per share, which beat analysts' earnings expectations of -$0.51 per share by 0.99%. After releasing the results, Orchestra BioMed Holdings Inc (NASDAQ:OBIO) was up by 7.94% in one day.

Based on the one-year price targets offered by 6 analysts, the average target price for Orchestra BioMed Holdings Inc (NASDAQ:OBIO) is $13.50 with a high estimate of $20.00 and a low estimate of $10.00. The average target implies an upside of 257.62% from the current price of $3.78.

Based on GuruFocus estimates, the estimated GF Value for Orchestra BioMed Holdings Inc (NASDAQ:OBIO) in one year is $6.76, suggesting an upside of 79.07% from the current price of $3.78.

Based on the consensus recommendation from 7 brokerage firms, Orchestra BioMed Holdings Inc's (NASDAQ:OBIO) average brokerage recommendation is currently 2.0, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.